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InsectDirect systemAbstract Several prokaryotic and eukaryotic expression systems have been used for in vitro pro-
duction of viruses’ proteins. However eukaryotic expression system was always the first choice for
production of proteins that undergo post-translational modification such as glycosylation. Recom-
binant baculoviruses have been widely used as safe vectors to express heterologous genes in the cul-
ture of insect cells, but the manipulation involved in creating, titrating, and amplifying viral stocks
make it time consuming and laborious. Therefore, to facilitate rapid expression in insect cell, a plas-
mid based expression system was used to express herpes simplex type 1 glycoprotein D (HSV-1 gD)
and varicella zoster glycoprotein E (VZV gE). Recombinant plasmids were generated, transfected
into insect cells (SF9), and both glycoproteins were expressed 48 h post-infection. A protein with
approximately molecular weight of 64-kDa and 98-kDa for HSV-1 gD and VZV gE respectively
was expressed and confirmed by SDS. Proteins were detected in insect cells cytoplasm and outer
membrane by immunofluorescence. The antigenicity and immunoreactivity of each protein wereein using
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a novel plasmid based expression system in iconfirmed by immunoblot and ELISA. Results suggest that this system can be an alternative to the
traditional baculovirus expression for small scale expression system in insect cells.
 2016 The Authors. Production and Hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Herpes simplex viruses (HSV) and varicella-zoster virus (VZV)
are responsible for a wide range of human diseases with over-
lapping degree in clinical presentations and the human patho-
gen that can produce a wide range of mucocutaneous
manifestations. The infections extending from skin and genital
lesions to the central nervous system, can be caused by bacte-
ria, viruses, fungi, or parasites (Wong et al., 2016). The biolog-
ical and scientific nature of the disorders caused by these
viruses has been elucidated, at least in part, during the past
150 years. The researchers are proving the infectious nature
of the pathogens, understanding the basic concepts of latency
and reactivation, devising specific antiviral agents, and
sequencing the entire viral genomes were all products of the
biological and molecular revolution of biomedical research
of the 20th century. Although herpes infections do not attract
the level of public attention that they did before the era of
HIV/AIDS, they are still of major medical importance in the
realms of dermatology, paediatrics, infectious diseases, obstet-
rics and gynaecology, and neurology (Steiner et al., 2007). Her-
pes simplex type 1 is responsible for 90–95% of cases while
herpes simplex type 2 (HSV-2) contributes the remaining 5–
10% of herpes simplex encephalitis (HSE) cases (Stone and
Hawkins, 2007). Meningitis, encephalitis, and myelitis are
caused by HSV viruses in the CNS disease. HSV-2 has more
often been linked to recurrent aseptic meningitis than HSV-1
and causes neurological complications more often than most
other viruses. However, HSV-2 meningitis has also been recog-
nised as a significant cause of morbidity and mortality in
immunocompromised patients (Akya et al., 2015).
VZV a member of herpesvirus family causes chickenpox
(varicella), generally in infants, may reactivate decades later
to produce shingles (zoster). The neurological complications
of VZV are rarely seen during the primary infection (varicella
cerebellitis) and more often during the reactivation phase.
However, most severe neurological complications occur in
immunocompromised patients and include aseptic meningitis,
encephalitis with vasculitis, ventriculitis, severe necrotising
myelitis, post-herpetic neuralgia and leukoencephalopathy
(Corti et al., 2015).
Acute disseminated encephalomyelitis (ADEM) is an
uncommon disorder of the central nervous system that occurs
after viral illness or vaccination. ADEM resulting from VZV
vaccination is estimated to occur in 1 in every 1000 cases of
ADEM (Idrissova et al., 2003). Symptoms usually occur after
days (2–30 days) of neurological illness and are characterised
by an acute onset of focal neurological signs and encephalopa-
thy (Sonneville et al., 2009). Symptoms include; neck stiffness,
seizures and fever, and although the latter is not a constant
feature, it is present in 75% of severe cases (Sonneville et al.,
2009). Clinical diagnosis of these infections is mostly based
on the presence of characteristic vascular eruption; however,
it can be similar to other viral or nonviral skin infections, A.M. et al., Expression of variable vir
nsect cell. Saudi Journal of Biological S(Crum-Cianflone, 2008) Therefore, confirmatory test is
needed, this can be done by a number of laboratory tests such
as virus isolation, direct or indirect immunofluorescence,
detecting viral DNA by polymerase chain reaction (PCR),
and detecting antibody responses to the viruses using
enzyme-linked immunosorbant assay (ELISA). Serological
assays using viral antigen play a role in diagnosis and epidemi-
ological studies, however these assays are varying in sensitivity,
specificity and in the methodology for detecting HSV and VZV
antibody.
Over the past 20 years, the baculovirus expression system
has become one of the most popular vehicles for the produc-
tion of large quantities of recombinant protein. Baculovirus
protein expression is a eukaryotic based expression system
and thus offers protein modification and a processing pattern
similar to those of higher eukaryotic cells. Although recent
advances in baculovirus technology include the development
of a wide variety of transfer vectors and cloning methods, sim-
plified recombinant virus isolation, quantification methods,
and development of cell culture technology have improved.
However, the manipulation involved in creating, titrating,
and amplifying viral stocks makes it time consuming and labo-
rious. Therefore, in this study a plasmid based expression sys-
tem InsectDirect (Novagen, Merck, USA) was used to express
the full length of HSV-1 gD and VZV gE recombinant glyco-
proteins in insect cells. The present study demonstrates that the
InsectDirect system employs an optimal expression vector
with high efficiency for transfection and it seems to be an ideal
system for rapid expression of virus glycoproteins in insect
cells.
2. Materials and methods
2.1. Genotyping of HSV-1 gD and VZV gE DNA fragment
Genotyping was performed with specific primers used to
amplify the full open reading frame of each DNA region
encodes HSV-1 gD and VZV gE proteins, for HSV-1 gD a
sense primer HSVgDF (50-CAGGGACCCGGTATGGGG
GGGGCT-30) and reverse primer HSVgDR (50-GGCACCA
GAGCGTTCTAGTAAAACAAGGGCTGG-30), for VZV
gE, forward primer VZVgEF (50-CAGGGACCCGGTATG
GGGACAGTTAATAAA-30) and reverse primer VZVgER
(50-GGCACCAGAGCGTTTCACCGGGTCTTATCTAT-30).
To generate vector specific compatible overhangs, the forward
and reverse primers were incorporated with victor specific
sequence (under lined). Master mix reaction were consisting
of 45 ll [5 ll 10  buffer (50 mM KCl, 1.5 mM MgCl2
and10 mM Tris–HCl; pH 8.3), 1 ll (10 mM) of dNTP, 1 ll
of each oligonucleotide primer, 36.5 ll SDW and 0.5 U of
AmpliTaq Gold polymerase]. 5 ll of each sample were added
including a negative control to a final volume of 50 ll. The
cycling programme used included a single initial denaturation
at 94 C for 6 min followed by 40 cycles of denaturation atuses as herpes simplex glycoprotein D and varicella zoster gE glycoprotein using
ciences (2016), http://dx.doi.org/10.1016/j.sjbs.2016.05.003
Recombinant HSV and VZV antigen, InsectDirect cell Baculovirus expression system 394 C for 1 min, annealing at 58 C for 1 min, extension at
72 C for 1 min and a final step of 72 C for 5 min. Amplification
of VZV gE was carried out as above except the extension time
was extended to 1.30 min at 72 C. 5 ll of each sample were
added including a negative control to a final volume of 50 ll.
PCR products were then purified using a modified Microcon
centrifuge method (YM-100 Centrifugal F Micron YM-100
Kit) and analysed by 2% agarose gel electrophoresis (Heaton
et al., 2015).
2.2. Recombinant plasmid construction
To construct the recombinant plasmid, the ligation-
independent cloning (LIC) strategy was used. Briefly, the insert
with overhangs prepared by PCR was treated with T4 DNA
polymerase in the presence of dATP, and then annealed with
the pIEx/Bac-3 3C/LIC vector (Novagen, Merck, USA) con-
taining the hr5 (homologous region 5) enhancer and the ie1
(immediate early 1) promoter from Autographa californica
nuclear polyhedrosis virus (AcNPV). Then, the annealed com-
plex was transformed into E. coli host (NovaBlue GigaSin-
glesTM Competent Cells, K-12 strain (Novagen, Merck, USA).
Screening for the recombinant plasmid was carried out using
PCR, in one stage, vector-specific primers (IE1 Promoter
and IE1 Terminator) were used at the both ends, and in other
stages one vector-specific primer was used in combination with
HSV-1 gD or VZV gE gene primers. Recombinant plasmid
was then purified using MobiusTM 200 kit (Novagen, Merck,
USA), and then analysed using 1% agarose gel electrophoresis
in Tris–phosphate buffer and then stained with ethidium bro-
mide solution for 10 min and viewed in an ultraviolet
transilluminator.
2.3. Insect cell transfection
Protein expression of each virus was carried out using a 10 ml
suspension culture of Spodoptera frugiperda (SF9) cells (Nova-
gen, Merck, USA). Briefly 8 ml of fresh dilution of SF9 cells
(1  107 viable cells/ml) were prepared from an exponentially
growing shake culture. In a 1.5 ml tube 20 ll of plasmid
DNA (20 lg) was diluted in 1 ml of BacVector Insect Cell
Medium (Novagen, Merck, USA). At the same time a 100 ll
of GeneJuice Transfection reagent (Novagen property) was
diluted in 1 ml of the same media in a 1.5 ml tube. The diluted
plasmid DNA was then added dropwise to the diluted Gene-
Juice Transfection reagent and was mixed gently to avoid pre-
cipitation, and then left at room temperature for 15 min.
Finally, the entire volume was added to the cells and incubated
for 48 h at 150 rpm on orbital shakers at 28 C with caps con-
taining 0.2 lm filter until maximum target protein expression
was achieved (2–3 days).
2.4. Proteins solubilisation
Since a large amount of the full glycosylated form of HSV-1
gD and VZV gE was integrated into SF9 outer membrane,
therefore extracting the proteins from cells membrane, was
an essential step in protein purification. Earlier study by
Wang et al. (2006) was performed in which the protein purifi-
cation carried out using the non-ionic detergent (Pentaethylene
glycolmonodecylether (C10E5)) and this study was performedPlease cite this article in press as: Al-Sulaiman, A.M. et al., Expression of variable vir
a novel plasmid based expression system in insect cell. Saudi Journal of Biological Swith some minor modifications. Briefly, a suspension culture of
SF9 cells (2.5  108) was transfected with the recombinant
plasmid and then incubated for 2 days on orbital shakers at
28 C. After incubation cells were harvested by low speed cen-
trifugation (2000 g  10 min), and washed 3 times with ice-
cold phosphate buffer solution (PBS, pH 7.3). Cells pellet
(5  107/ml) was then resuspended in an ice-could solubilising
buffer (20 mM Tris–HC, pH 7.8, 2 mM Phenylmethylsulfonyl
fluoride (PMSF), 1 mM Tosyl-Lys-chloromethylketone
(TLCK)) and then the same volume of buffer containing 2%
(v/v) of C10E5 was added (final detergent concentration
1%). Cells suspension was then incubated on ice for 2 h. After
incubation cells debris was removed by low speed centrifuga-
tion (2000 g  10 min) and supernatant was then ultracentrifu-
gated (70000 g  1 h, 4 C). 50 ll of the final supernatant
(containing solubilised protein) were stored at +4 C for pro-
tein analysis and the remaining was used in the purification
step.2.5. Protein purification
Protein purification was carried out using his-bind purification
kit (Novagen, Merck, USA). Briefly, in a 20 ml tube 500 ll of
Ni–NTA his-binding resin was mixed with the remaining of the
solubilised protein (10 ml). Tube was then placed on orbital
shakers (150 rpm) at room temperature for 2 h. Purification
column was assembled (chromatography column + 15 ml col-
lecting tube), and then the entire volume was added into the
reservoir of the column. Column was left to flow by gravity
(5 to 10 min) and then transferred to a new collecting
15 ml tube and 4 ml of washing buffer was added to the col-
umn and left to flow. The washing step was repeated once
and the column was transferred to a new collecting tube fal-
lowed by the addition of 1 ml of elution buffer (Novagen prop-
erty) was added. 50 ll of each tube were stored at +4 C for
protein analysis. The eluted protein was then stored in
70 C at 100 ll aliquot for protein characterisation.2.6. Recombinant proteins characterisation [indirect
immunofluorescence (IF)]
Indirect immunofluorescence analysis was performed using
fluorescein-conjugated rabbit anti mouse IgG (cell surface,
cytoplasmic). Briefly, to examine cell surface immunofluores-
cence, cells were incubated with mouse anti HSV gD or VZV
gE monoclonal antibody for 1 h at 37 C with gentle agitation,
washed with PBS, fixed on Lab-Tek chamber slides with 100%
cold acetone for 10 minutes, stained with fluorescein-
conjugated rabbit anti-mouse IgG antibody for 1 h at 37 C,
and then rewashed. To examine intracellular (total cell)
immunofluorescence, cells were washed with PBS, fixed on
Lab-Tek chamber slides with acetone for 20 min and incubated
with mouse anti gD or gE mouse monoclonal antibody for 1 h
at 37 C. Cells were then washed 3 times with PBS, stained
with fluorescein-conjugated rabbit anti-mouse IgG antibody
for 1 h at 37 C washed again and left to air dry for 10 min.
A negative control (non infected cells) was included in each
slide for comparison. Slides were then examined with an inci-
dent light fluoresce microscope (Dialux 20 EB, Leitz Wetzlar,
Germany).uses as herpes simplex glycoprotein D and varicella zoster gE glycoprotein using
ciences (2016), http://dx.doi.org/10.1016/j.sjbs.2016.05.003
Figure 1 This figure represents the details of the 3C/LIC cloning
strategy, PCR product containing the 5LIC extension were treated
with LIC-qualified T4 DNA polymerase in the presence of dATB,
and then annealed to the 3C/LIC vector.
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(SDS–PAGE)
Proteins were separated by sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS–PAGE) under dena-
turing reducing conditions. Briefly, 14 ll of sample (trans-
fected cells (5  103/ml), solubilised protein, purification
flow, first wash, second wash, and eluted protein) was mixed
with sample loading buffer (4 ll of NuPAGE LDS sample buf-
fer, 6 ll deionised water and 1 ll reducing agent). Samples
were heated at 70 C for 10 min and a 16 ll of each sample
was analysed using NuPAGE 4–12% Bis–Tris gel (Invitrogen,
Carlsbad, CA) for 45 min at 200V. Gel was then stained with
SimpleyBlueTM SafeStain (Invitrogen), and then removed from
the tank and placed into a plastic container, rinsed three times
for 5 min with 100 ml deionised water to remove SDS and buf-
fer salts. Excess water was drained and 20 ml of Coomassie
Blue stain was added and kept on a shaker for 1 h at room
temperature. For maximum staining sensitivity 20 ml of 20%
NaCl was added to the same water and left on the shaker
for another 2 h.
2.8. Immunoblot (western blot, dot blot)
Western blot analysis was carried out under denaturing reduc-
ing condition. After electrophoresis, proteins were transferred
to a polyvinylidene difluoride (PVDF, Invitrogen, Carlsbad,
CA). For dot blot 35 ll of each sample (transfected cells
(5  103/ml), solubilised protein, purification flow, first wash,
second wash, first elute and second elute) was transferred to
dot blot manifold I (Schleicher & Schuell, Germany) and
vacuum-absorbed onto a 0.45 l nitrocellulose membrane.
Each sample was washed three times with 100 ll of washing
buffer (10 mM PBS, 0.05% Tween 20) and then air-dried. Both
membranes were then blocked in blocking buffer (2.5 mg
skimmed milk, 50 ml PBS Ph 7.3, 0.1% Tween 20) overnight
at 4 C. Membranes were then incubated with anti-HSV gD
or VZV gE monoclonal antibody (Abcam) diluted in blocking
buffer for 1 h at 37 C with gentle agitation, followed by 3
washing steps each of 5 mentis and incubated with
peroxidase-labelled antibody diluted in diluent buffer
(10 mM PBS + 0.1% Tween) for 1 h at 37 C. Each mem-
brane was washed and then incubated with one tablet of
SIGMA FASTTM (4-chloro-2-methylbenzenediazonium/
3-hydroxy-2-naphthoic acid 2,4-dimethylanilide phosphate)
dissolved in 10 ml of deionised water on a rotor at room
temperature until the bands appeared. The membrane was
rinsed with distiled water and left to dry on filter paper.
3. Results
3.1. Determining the sequence of gD of HSV-1 and VSV gE
Nine complete sequences for the full HSV-1 gD gene and 12
sequences for the VZV gE gene obtained from Gene Bank were
analysed and compared with each other. Alignment analyses
used the Bio Edit Sequence Alignment Editor Programme.
Both HSV-1 gD and VZV gE sequences were found to be iden-
tical for all isolates. The full length of HSV-1 was 1185 bp
spanning the region 138,419–139,603 bp of HSV-1 genome,Please cite this article in press as: Al-Sulaiman, A.M. et al., Expression of variable vir
a novel plasmid based expression system in insect cell. Saudi Journal of Biological Sand the full length of VZV gE was 1872 bp spanning the region
115808 to 117679 of the VZV genome. The sequence of HSV-1
gD (accession NC001348) and VZV gE (accession NC001348)
gene was selected for this study.
3.2. Construction of recombinant plasmid
The strategy used for construction of the recombinant plas-
mids containing the entire length of HSV-1 gD (1185 bp)
and VZV gE (1875 bp) DNA fragment is shown in Fig. 1. A
starting codon (ATG) was incorporated in 50-end after the
overhang sequence of each forward primer and termination
codon (TAG) at the 30 end of each reverse primer for each
virus and there were no HSV-1 or VZV noncoding sequences
present after the termination codon. The complete DNA frag-
ments of each virus plus the overhang sequence were then gen-
erated by PCR and annealed within the 5LIC cloning site of
the pIEx/Bac-3 3C/LIC vector. PCR secreting for the recombi-
nant plasmid using victor-specific primer or in combination
with insert-specific primer has confirmed that PCR product
was inserted into the cloning site in the right orientation.
The plasmid vector is incorporated with 10-His. Tag sequence
at the N-terminal to allow protein
3.3. Purification by affinity chromatography (Plasmid DNA
Purity and Concentration)
Plasmid concentration was determined using UV spectropho-
tometry. The plasmid DNA yield with A260/A280 absorbance
>1.7 was found to be 25 lg/ml and 30 lg/ml for HSV-1 gD
and VZV gE respectively. The plasmid copy number for each
virus insert was calculated using the formula: Plasmid molecularuses as herpes simplex glycoprotein D and varicella zoster gE glycoprotein using
ciences (2016), http://dx.doi.org/10.1016/j.sjbs.2016.05.003
Recombinant HSV and VZV antigen, InsectDirect cell Baculovirus expression system 5weight = Number of base pairs  molecular mass of
deoxynucleotide base pair For HSV-1 gD plasmid the molecu-
lar weight of the pIEx/Bac-3 3C/LIC (6763 bp) plus HSV-1 gD
(1242) = (6.763 + 1.242)  103  660 = 5.28  106 Dalton.
Each 1 Mole of plasmid contains 5.28  106 g and with Avo-
gadro’s number = 6.023  1023 then each plasmid contains
6.023  1023 molecules Using the UV spectrophotometer the
concentration of HSV-1 gD plasmid was found to be 25 lg/ml,
therefore: 25 lg of recombinant plasmid contains:
6.023  1023  20/5.28  106  106 = 22.81  1011 copy/ml
(11.4  109 copy/5 ll). For VZV gE plasmid the molecular
weight the pIEx/Bac-3 3C/LIC (6763 bp) plus VZV gE
(1934) = (6.763 + 1.934)  103  660 = 5.74  106 Dalton;
30 lg of recombinant plasmid contains: 6.023  1023 
20/5.74 106 106= 20.99 1011 copy/ml (10.5 109 copy/5 ll).
3.4. InsectDirectTM system
In the InsectDirectTM expression system HSV-1 gD and VZV
gE were expressed using 6 well plates and 10 ml suspension
cultures. Cells were examined daily (24, 48 and 72 h p.i) no
clear signs of infection were observed in comparison with
uninfected cells. Transfected cells continued to grow normallyA
C
E
Figure 2 Expressions of HSV-1 gD and VZV gE in insect cells, cells
cells were analysed for synthesis and localisation of the viral glycoprot
gD and gE were detected in the cytoplasms of the acetone-fixed transfe
and D). Neither antibody was reacted with the negative control (E an
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inhibition. However, after 72 h p.i signs resembling those of an
unhealthy culture, such as floating cells, appearance of
granules and cells lysis were observed in both transfected
and non-transfected cells. Protein expression was observed
by 48 h (50–65% of cells) and maximum protein expression
was found at 72 h p.i (95% of cells) as assessed by immunoflu-
orescence assay.
3.5. Protein purification and quantification
Since the large amount of the fully glycosylated form of HSV-1
gD and VZV gE was found to be integrated into the outer
membrane of SF9 cells, extraction of the proteins from the cell
membrane was considered an essential step in protein purifica-
tion. A number of methods were evaluated such as disruption
of cell membrane with glass beads or solubilising membrane
protein with detergents. Use of a non-ionic detergent
(C10E5) was found to be the most suitable method. Protein
quantification results using the BCA assay showed that yields
of purified protein from the small scale suspension cultures of
the InsectDirectTM expression system ranged from 25 to
60 lg/10 ml, whereas 130 to 210 lg/10 ml was obtained withB
F
D
were infected with recombinant plasmid. At 72 h p.i, transfected
eins within the cell and at the cell surface. Expressed glycoproteins
cted cells (A and C) and on cells membrane of the unfixed cells (B
d F).
uses as herpes simplex glycoprotein D and varicella zoster gE glycoprotein using
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Figure 4 Fig. 3 dot blot analyses of HSV-1 gD (A) and VZV gE
(B) recombinant protein, samples were transferred to dot blot
manifold and vacuum-absorbed onto a 0.45 l nitrocellulose
membrane, incubated with the selected antibody and then incu-
bated with peroxidase-labelled antibody. Lane 1 transfected cells;
Lane 2 solubilised protein; Lane 3 purification flow; Lane 4 first
wash; Lane 5 negative control (non-infected cells were subjected to
the same procedure of the purification process); Lane 6 second
wash; Lane 7 eluted recombinant protein.
6 A.M. Al-Sulaiman et al.the BacMagic expression system. For large scale protein
expression; the purified protein yield of the BacMagic expres-
sion system ranged from 0.5 to 1.5 mg/100 ml. An example of
the protein quantification method and the mechanism of
action of detergent on integral and peripheral membrane
protein.
3.6. Recombinant proteins characterisation (analysis of
immunofluorescence)
To determine the efficiency of protein expression and the local-
isation of the expressed proteins an indirect immunofluores-
cence staining was carried out using anti HSV gD and VZV
gE monoclonal antibody (Fig. 3). Both expressed glycopro-
teins were detected in the cytoplasms of the acetone-fixed
transfected cells (Fig. 2A and C) and at cells membrane of
the unfixed cells (Fig. 2B and D). To determine the specify of
the staining in the assay, a transfected cell with recombinant
plasmid containing HSV gD were reacted with VZV gE mon-
oclonal antibody and vice versa, however no staining was
observed (Fig. 2E) in comparison with negative control
(Fig. 2F). Expressed proteins were observed at 48 h p.i with
a percentage of positive cells that ranged from 50% to 75%.
However, it was best observed at 72 h (95%), therefore this
time were selected for protein expression experiments.
3.7. SDS–PAGE and immunoblot analysis
The effects of various harvesting time duration for the produc-
tion of recombinant proteins were examined by SDS–PAGE
analysis. SF9 cells were transfected with each recombinant
plasmids and the synthesis of each protein was analysed using
SDS–PAGE at different harvesting time points (48, 72 and
96 h). Results showed that both recombinant proteins were
expressed in SF9 cells at 48 h; however, the peak of expression
was obtained at 72 and 96 h p.i. Coomassie blue-stained SDS–
PAGE showed that recombinant HSV-1 gD and VZV gE
appeared as single bands with a molecular weight of 64-kDa
and 98-kDa respectively. Western blot and dot blot analysis
of the expressed proteins using monoclonal anti HSV-1 gD
and VZV gE has also showed that each protein was expressed
in SF9 cell. In comparison with the molecular weight markers,
HSV-1 gD and VZV gE appeared as 64-kDa and 98-kDa
respectively. SDS–PAGE and immune blot analysis of recom-A
64 kd
Figure 3 (A) Time course of HSV-1 gD expression analysed by SDS
Please cite this article in press as: Al-Sulaiman, A.M. et al., Expression of variable vir
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proteins. This suggests that the expressed proteins are retained
in the cell or in the cell membrane and it is not secreted into the
medium (Fig. 4).
4. Discussion
Conventional methods for detecting CNS infection with alpha
herpesviruses (HSV-1, HSV-2, VZV) and determining intrathe-
cal IgG antibody productions are time and sample consuming.
They can exhaust up to 1 ml of sample and the assays may take
more than 24 h to produce results. A more rapid assay requir-
ing minimal sample volume and time to produce results would
therefore be an important diagnostic tool for use in patients
with CNS infection. The overarching aim of the present study
was to improve the diagnosis of viral CNS infections.
In this current study, we assisted a novel way for protein
expression system termed as InsectDirect. A number of
prokaryotic and eukaryotic expression systems have been used
for in vitro production of HSV gD and VZV gE including bac-
teria (Watson et al., 1982), yeast (Stanberry et al., 1987; Van
Kooij et al., 2002), Vaccinia (Paoletti et al., 1984), mammalian
cells (Stanberry and Myers, 1988; Haumont et al., 1996) and
baculovirus (Krishna et al., 1989; Ghiasi et al., 1991;
Landolfi et al., 1993; Sisk et al., 1994; Kimura et al., 1997;
Ikoma et al., 2002). Although E. coli and yeast expressionB
98 kd 
–PAGE. Lane 1: molecular weight marker; Lane 2–5: 2–5 day p.i.
uses as herpes simplex glycoprotein D and varicella zoster gE glycoprotein using
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resource for production of large quantities of proteins,
expressed by these systems lack many of the post translational
modifications associated with proteins produced by eukaryotic
cells (glycosylation and cleavage). Other systems are also
limited in terms of safety and the quantity of recombinant
protein produced. However, baculovirus expression systems
have been found to be the most useful system to produce fully
functional glycosylated glycoproteins similar to their authentic
counterparts from mammalian cells (Fotouhi et al., 2008).
This study showed that HSV-1 gD was expressed in insect
cells, and appeared as 48 kd, however it was slightly smaller
than virion HSV-1 gD made in baby hamster kidney (58 kd).
The study found that antibody taken from mice infected with
HSV-1 reacted with both proteins. Immunisation of mice with
an extract of the expressed gD induced a high titre of comple-
ment and independent neutralising antibody (Krishna et al.,
1989). In a further study to investigate the possibility of using
baculovirus to express a large quantity of HSV-1 gD, Ghiasi
et al. (1991), constructed a recombinant baculovirus contain-
ing the full-length of HSV-1 gD using HSV-1 strain KOS as
the template. In the study, SF9 cells were transfected and the
recombinant protein was purified using immunoaffinity selec-
tion. Characterisation of the recombinant protein was carried
out using SDS, immunofluorescence and western blot. The
study showed that recombinant protein was expressed, trans-
ported to the membrane of SF9 cells and reacted with gD
specific antibody. Although the expressed protein was slightly
bigger than that reported previously (52 kd), it still appeared
to be slightly smaller than HSV-1 gD made in Vero cells.
Landolfi et al. (1993) also expressed the full-length of HSV-2
gD, aiming to study the viability of using gD2 as a vaccine
subunit.
Although the baculovirus system has been widely used for
the production and study of structural and non-structural pro-
teins of a number of viruses including, human polyomavirus,
poliovirus, influenza virus, human papillomavirus and her-
pesvirus (Possee, 1986; Neufeld et al., 1991; Ghiasi et al.,
1991; Sisk et al., 1994; Landolfi et al., 1993; Ghiasi et al.,
1994; Kimura et al., 1997; Kimura et al., 1998; Ikoma et al.,
2002; Giavedoni, 2005; Hsu et al., 2009) traditional bac-
ulovirus expression methods have several disadvantages in
terms of low frequency of recombination, protein production
and the requirement for several rounds of plaque purification
(Fotouhi et al., 2008).
The InsectDirect System is a plasmid-based expression sys-
tem that enables rapid small-scale expression in insect cells. It
can be scaled up to isolate milligram quantities of target pro-
tein without the need to generate a recombinant baculovirus
and this expression system employ a combination of expres-
sion vector, high efficiency transfection reagent, lysis reagents
and Ni–NTA His-Bind Resin for affinity purification of his-tag
fusion proteins (Loomis et al., 2005). Immunoreactivity of the
recombinant proteins was also studied by immunoblot (west-
ern blot and dot blot) using monoclonal antibody targeted
against each protein. In immunoblot, samples (cell lysate), sol-
ubilised protein, purification flow and wash, transfection
media and negative control (solubilised protein from unin-
fected cells) were analysed using the appropriate monoclonal
antibody. Results showed that cell lysate, solubilised proteins
and purified proteins samples reacted with the monoclonal
antibody, whereas the negative control as well as the mediaPlease cite this article in press as: Al-Sulaiman, A.M. et al., Expression of variable vir
a novel plasmid based expression system in insect cell. Saudi Journal of Biological Sof the transfected cells did not. This confirmed that both pro-
teins were expressed and either retained in the cell or cell mem-
brane and not secreted into the medium. Such results are in
accordance with previous studies (Ghiasi et al., 1991; Wu
and Forghani, 1997; Fotouhi et al., 2008). Western blot results
showed that gD and gE were expressed and present as proteins
of relative molecular weight of 64 kd and 98 kd respectively. In
the case of HSV-1 gD the observed size (64 kd) was larger than
any previously reported recombinant protein expressed in
insect cells using other baculovirus expression systems
(Krishna et al., 1989; Ghiasi et al., 1991; Fotouhi et al.,
2008). Such results suggest that in this project the expressed
gD underwent more extensive post-translation addition of car-
bohydrate than other reported proteins using this system. In
the case of VZV gE the observed size (98 kd) was similar to
that reported by Wu and Forghani (1997) and bigger than that
reported by Olson et al. (1997). In both studies VZV gE was
expressed using traditional baculovirus systems under the con-
trol of the polyhedron promoter. The results obtained from
immunoblot and IF assays confirmed that these recombinant
proteins were antigenically and functionally similar to their
authentic counterparts, therefore production and purification
of these proteins was carried out. As stated previously, one
of the unique features of using this expression system is the
simplicity of purification of the recombinant protein. The plas-
mid contains a 10 polyhistidine tag sequence upstream of the
cloning site (3C/LIC). In this case the fused protein will be
expressed with an N-terminal his-tag, which can be used later
to purify the expressed protein using the nickel-nitrilotriacetic
acid (Ni–NTA) system. In addition, expression of the target
protein immediately downstream of the HRV 3C protease
cleavage site helps the removal of the encoded fused sequences
after purification of the recombinant protein if it is needed. In
general, HSV-1 gD and VZV gE glycoproteins were expressed
as early as 2 days p.i, yields the same protein with no differ-
ences in size or immunoreactivity. The only differences found
between the two systems were the protein yields. Such results
were expected because each system was originally designed
for different purposes.
5. Conclusion
Although the InsectDirect system protein yield can be scaled
up by using several culture bottles, it is not cost effective for
production of recombinant protein in large quantities, since
reagents such as plasmid purification kits and insect GeneJuice
are required constantly for protein expression. Results suggest
that this system can be an alternative to the traditional bac-
ulovirus expression for small scale expression screening system
in insect cells.
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